Track topics on Twitter Track topics that are important to you
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Palliative Lattice Stereotactic Body Radiotherapy (SBRT) articles that have been published worldwide.
We have published hundreds of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) news stories on BioPortfolio along with dozens of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) Clinical Trials and PubMed Articles about Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) Companies in our database. You can also find out about relevant Palliative Lattice Stereotactic Body Radiotherapy (SBRT) Drugs and Medications on this site too.
Palliative antalgic treatments represent an issue for clinical management and a challenge for scientific research. Radiotherapy (RT) plays a central role. Techniques such as stereotactic body radiotherapy (SBRT) were largely investigated in several phase 2 studies with good symptom response, becoming widely adopted. However, evidence from randomized, direct comparison of RT and SBRT is still lacking.
Stereotactic body radiotherapy (SBRT) is an effective treatment for spinal metastases in the vertebral body. There is variation between practitioners about appropriate target delineation. As such, we compare tumor control, rates of compression fracture, and pain control for patients treated with stereotactic body radiotherapy (SBRT) for spinal metastases treated to lesion only (LO) versus the full vertebral body (FVB).
Understanding prostate-specific antigen (PSA) kinetics after radiotherapy plays a large role in the management of prostate cancer (PCa) patients. This is particularly true regarding establishing expectations regarding PSA nadir (nPSA) and PSA bounces, which can be disconcerting. As increasingly more patients are being treated with stereotactic body radiotherapy (SBRT) for low- and intermediate-risk PCa, it is imperative to understand the PSA response to SBRT.
Treatment of spine bone metastases with stereotactic radio-therapy (SBRT) may produce greater pain relief than palliative radiotherapy.
Stereotactic body radiotherapy (SBRT) is a young technology that can deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body. Various technical solutions co-exist nowadays, with particular features, possibilities and limitations. Health care authorities have currently validated SBRT in a very limited number of locations, but many indications are still under investigation. It is therefore challenging to accu...
Although several prospective studies have reported the efficacy of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC), treatment-related toxicity varies and has not been determined. Therefore, the authors evaluated the safety and efficacy of SBRT for patients with HCC in a hepatitis B virus-endemic area.
The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT.
and purpose: To assess the efficacy and safety of salvage stereotactic body radiotherapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiotherapy.
Stereotactic body radiotherapy (SBRT) results in excellent local control of stage I non-small cell lung cancer (NSCLC). Radiobiology models predict greater tumor response when higher biologically effective doses (BED) are given. Prior studies support a BED ≥100 Gy with SBRT; however, data is limited comparing outcomes after various SBRT regimens. We therefore sought to evaluate national trends and the effect of using "low" versus "high" BED SBRT courses on overall survival (OS).
We retrospectively compared stereotactic body radiotherapy (SBRT) with conventionally fractionated radiotherapy (CFRT) for a solitary lung tumor after resection of a non-small cell lung cancer (NSCLC), due to a lack of data concerning whether SBRT or CFRT is more effective in this setting.
The objective of this study was to evaluate a single institution's experience with stereotactic body radiotherapy (SBRT) in treating malignant adrenal lesions, as well as the prognostic value of systemic inflammation biomarkers.
Early stage lung cancer is treated with stereotactic body radiotherapy (SBRT) in patients unfit or unwilling to undergo surgical resection. Some patients' comorbidities are so severe that they are unable to even undergo biopsy. Clinical diagnosis without biopsy before SBRT has been utilized, but there are limited data on its efficacy.
Spinal cord tolerance data for stereotactic body radiotherapy (SBRT) were extracted from published reports, reviewed and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (D) are estimated to be associated with a 1 - 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions and 25.3 Gy in 5 fractions. For re-irradiation SBRT delivered in 1 to 5 fractions, reported factors a...
The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC).
Elekta XVI 5.0 allows for four-dimensional cone beam computed tomography (4D CBCT) image acquisition during treatment delivery to monitor intrafraction motion. These images can have poorer image quality due to undersampling of kV projections and treatment beam MV scatter effects. We determine if a universal intrafraction preset can be used for stereotactic body radiotherapy (SBRT) lung patients and validate the accuracy of target motion characterized by XVI intrafraction 4D CBCT.
Surgery is the gold standard therapy for patients with early-stage non-small-cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) may provide as an alternative for patients who are medically inoperable or refuse surgical resection. The optimal treatment (SBRT or surgery) for patients with early-stage NSCLC is not clear.
Retrospective evaluation of stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC).
The aim of this study was to investigate radiation-induced tumour vascular damage and its impact thereof on the outcome of stereotactic body radiotherapy (SBRT).
Radiofrequency ablation (RFA) is a standard ablative modality for small liver malignancies. Stereotactic body radiotherapy (SBRT) has emerged although yet suffers a lack of high-level evidence. We performed meta-analyses and a systematic review to integrate the literature and help in clinical decision-making.
Although stereotactic body radiation therapy (SBRT) is an attractive non-invasive approach for liver irradiation, it presents specific challenges associated with respiration-induced liver motion, daily tumor localization due to liver deformation and poor visualization of target with respect to adjacent normal liver in CT. We aim to identify potential hazards and develop a set of mitigation strategies to improve the safety of our liver SBRT program, using failure mode and effect analysis (FMEA).
Previous comparisons of surgery and stereotactic body radiotherapy (SBRT) for early-stage (ES) non-small cell lung cancer (NSCLC) did not account for the extent of regional lymph node examination (LNE) during surgery.
Stereotactic body radiotherapy (SBRT) for prostate cancer (PCa) is gaining interest by the recent publication of the first phase III trials on prostate SBRT and the promising results of many other phase II trials. Before long term results became available, the major concern for implementing SBRT in PCa in daily clinical practice was the potential risk of late genitourinary (GU) and gastrointestinal (GI) toxicity. A number of recently published trials, including late outcome and toxicity data, contributed to...
The quality of stereotactic body radiation therapy (SBRT) treatment plans for early stage lung cancer are unknown outside of peer-reviewed publications. Thus, a study was conducted to crowdsource and analyze a variety of lung SBRT treatment plans from around the world.
Stereotactic body radiotherapy has emerged as an attractive alternative to conventional radiotherapy for spinal metastases. However, it has limitations, including the need for advanced techniques and specific adverse effects. The present trial aimed to validate the feasibility and safety of stereotactic body radiotherapy in Japanese patients with spinal metastases.
The treatment of central lung tumors with Stereotactic Body Radiotherapy (SBRT) is challenged by the risk of excessive esophageal toxicity. To improve clinical decision making we aimed to derive Normal Tissue Complication Probability (NTCP) models in a patient cohort with central lung tumors treated with SBRT and to evaluate the currently used esophagus dose-constraints.